- Premium Stock Alerts
- Posts
- Profit Boost: Essential Pre-Market Stock Picks!
Profit Boost: Essential Pre-Market Stock Picks!
![](https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,format=auto,onerror=redirect,quality=80/uploads/asset/file/cedec129-4537-40b5-acf2-09834b7be645/1.png?t=1706685835)
You are receiving this newsletter as a subscriber to Premium Stock Alerts
Hello Part-time Traderβ¦π
US stocks were quiet on Friday evening as Wall Street aimed to stabilize following a slide in equities.
Despite Thursdayβs sell-off, market rotation remains the theme of the week. Heading into Friday, the S&P 500 and Nasdaq Composite are down 1.26% and 2.87%, respectively. Conversely, the Dow is up 1.66%, and the small-cap Russell 2000 has risen by 2.33%.
This divergence has been encouraging for some Wall Street professionals, who had been concerned that the market rally was becoming overly reliant on a few massive tech stocks.
In the political arena, investors are watching closely as Donald Trump intensifies his campaign with the Republican National Convention drawing to a close. Meanwhile, President Joe Biden faces mounting pressure from fellow Democrats to withdraw from the race.
Happening Today
β 10:40 AM ET β FOMC Member Williams Speaks
β 01:00 PM ET β U.S. Baker Hughes Oil Rig Count
β 03:30 PM ET β CFTC Crude Oil speculative net positions
β 03:30 PM ET β CFTC Gold speculative net positions
β 03:30 PM ET β CFTC Nasdaq 100 speculative net positions
β 03:30 PM ET β CFTC S&P 500 speculative net positions
Located 30 miles from Baltimore - Jeff Bezos has been quietly investing in one tiny company that's ground zero of a technology revolution that's going to change everything. Bank of America said the technology would be, "Bigger than fire and bigger than all the revolutions that humanity has seen."
And for investors who get in now profits could be massive - click here for full story.
Sponsored
PREMARKET SNAPSHOTπ
Market futures are mixed, with the S&P 500 and NASDAQ showing slight gains, while the Dow is down.
S&P500$5597.75 β¬οΈ 0.06% | Dow$40882.00 β¬οΈ 0.19% | NASDAQ$19920.75 β¬οΈ 0.11% |
SECTOR SNAPSHOTβ¨
The market faced a challenging day with widespread declines across most sectors. Health Care and Financials saw significant drops, while Consumer Discretionary and Industrials also posted notable losses. Energy stood out as the sole sector with positive movement, showing resilience amid broader market weakness. Defensive sectors like Consumer Staples and Utilities experienced minor declines, reflecting cautious investor sentiment. Overall, it was a tough day for the market with a broad-based retreat.
NAME | PRICE | %CHANGE |
---|---|---|
Consumer Discretionary | 1,524.55 | -1.28% π΄ |
Consumer Staples | 839.60 | -0.48% π΄ |
Energy | 715.75 | +0.33% π’ |
Financials | 719.93 | -1.28% π΄ |
Health Care | 1,714.22 | -2.29% π΄ |
Industrials | 1,062.96 | -0.73% π΄ |
Materials | 572.76 | -1.02% π΄ |
Real Estate | 254.50 | -0.81% π΄ |
Information Technology | 4,353.78 | -0.23% π΄ |
Communication Services | 302.45 | -0.29% π΄ |
Utilities | 355.85 | -0.06% π΄ |
His proprietary system can analyze over 6,000 stocks and trillions of data points. During a 15-year period his investment fund turned every dollar... into 4,000% return.
Hailed by Forbes as "The King of Quants," you can access his top 5 Stocks to Survive the Election Chaos isolated with this help of his proprietary system.
Click here for your FREE copy.
Sponsored
PreMarket Unusual Volume Stocks
π 60 Degrees Pharmaceuticals Inc (SXTP): 60 Degrees Pharmaceuticals Inc saw an extraordinary surge in trading activity with a volume of 10,569,975, far surpassing its average volume of 760.44. This massive uptick in interest resulted in a significant 68.09% price change, reflecting heightened market interest.
πServe Robotics Inc (SERV): Serve Robotics Inc experienced a substantial rise in volume, trading 5,297,583 shares compared to its average of 638.12. This dramatic increase in trading volume resulted in a 76.43% price change, indicating strong investor activity.
πSafe and Green Development Corp (SGD): Safe and Green Development Corp saw its trading volume surge to 6,337,357, significantly higher than its average of 3,502.27. The stock's price change of 11.47% mirrors this spike in trading volume.
πChina Automotive Systems Inc (CAAS): China Automotive Systems Inc's volume spiked to 61,542, a substantial increase from its average of 35.94. The stock's 10.54% price change highlights the impact of the increased trading activity.
πHafnia Ltd (HAFN): Hafnia Ltd saw its volume rise to 356,772, far exceeding its average of 328.15. Despite the increased trading activity, the stock experienced a modest -2.06% price change.
Dividend stocks are possibly the only investment where you have the opportunity for capital growth as well as income. Take Altria for example. $10,000 invested in Altria in 1991 with the dividends reinvested, would be worth $10.8 million today! And it pays an 8.5% dividend. Get two more high-yield stock tickers to buy and hold forever in the Ultimate Dividend Portfolio workshop.
Discover the 3-step trick to building your own Ultimate Dividend Portfolio
Sponsored
Premarket Picks
Augmedix, Inc. (AUGX) is trading at $2.2700 in pre-market, up 147.71% at 7:49 AM EDT after announcing a definitive agreement to be acquired by Commure, Inc. in an all-cash transaction valuing Augmedix at approximately $139 million. Augmedix stockholders will receive $2.35 per share, a 169% premium over the 30-day VWAP ending July 18, 2024.
Hawaiian Electric Industries, Inc. (HE) is trading at $17.46 in pre-market, up 36.94% at 7:52 AM EDT after tentatively agreeing to pay over $4 billion to resolve lawsuits related to last year's Maui wildfires. The proposed settlement awaits final approval and covers suits from thousands of homeowners and businesses..
Novo Integrated Sciences, Inc. (NVOS) is trading at $0.7239 in pre-market, up 20.19% at 7:57 AM EDT after announcing the commencement of disbursement for the monetization of a $78 million Standby Letter of Credit (SBLC). The initial disbursement releases a lien, with final distribution expected by August 2.
Below is a list of other hot stocks in pre-market today:
Pre Market Gainers | Pre Market Change | Pre Market Volume |
---|---|---|
SXTP | +35.93% | 6.63M |
SGD | +15.06% | 5.82M |
SERV | +81.18% | 3.30M |
NVOS | +21.20% | 1.05M |
S | +6.50% | 439.33K |
UNCY | +6.77% | 385.42K |
HE | +38.04% | 263.45K |
FCEL | +3.15% | 142.06K |
PRST | +2.98% | 112.50K |
AMIX | +3.70% | 103.94K |
I just closed a trade in 1 day for 200% gains on ANF in May. The trade cost just $50 to put on and we were in and out in less than 24 hours. You can get access, for a limited time, to a free, 30-minute training on exactly how I pulled this off. You'll be able to start landing these overnight wins yourself. You don't need any experience as an options trader. The trades are easy to buy and sell.
Get the free overnight options training here.
Sponsored
Important FDA
Recently Announced
Arcutis Biotherapeutics Inc. (ARQT) On July 9, 2024, Arcutis Biotherapeutics Inc. received FDA approval for their Roflumilast Cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children as young as six years old. This approval marks a significant advancement for the company in addressing atopic dermatitis, expanding their treatment options to both adult and pediatric patients.
Phathom Pharmaceuticals Inc. (PHAT) Phathom Pharmaceuticals Inc. announced on July 18, 2024, that the FDA has approved their VOQUEZNA (vonoprazan) 10 mg tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) in adults. This approval is a notable milestone for Phathom Pharmaceuticals, providing a new therapeutic option for patients suffering from this condition.
Rocket Pharmaceuticals, Inc. (RCKT) On June 28, 2024, Rocket Pharmaceuticals, Inc. received a Complete Response Letter from the FDA regarding their Biologics License Application (BLA) for KRESLADI (RP-L201), intended for the treatment of severe Leukocyte Adhesion Deficiency-I. This response indicates that the FDA has identified issues that need to be addressed before approval can be granted.
Orexo AB (ORXOY.OB) Orexo AB is anticipating an FDA decision on July 15, 2024, for their New Drug Application (NDA) for OX124, aimed at treating opioid overdose. The outcome of this decision is eagerly awaited, as it has the potential to provide a crucial treatment option in the ongoing battle against opioid overdoses.
Are you tired of your so-called "safe" income stocks slashing dividends while the share prices fall? I just revealed my safest most reliable and most consistent dividend stock - and it pays a sky high yield with dividends paid EVERY month. This company has also increased its monthly dividend twice a year every year for the past 10 years
Tap here to reveal the name of this stock for FREE
Sponsored
Upcoming Announcements
AstraZeneca PLC (AZN.L, AZN) On July 25, 2024, an FDA panel is set to review AstraZeneca PLCβs supplemental Biologics License Application (sBLA) for IMFINZI. This review will focus on the use of IMFINZI in combination with chemotherapy as a neoadjuvant treatment, followed by IMFINZI as monotherapy post-surgery, for adult patients with resectable non-small cell lung cancer. The decision could significantly impact treatment protocols for this type of cancer.
Alpha Cognition Inc. (ACOG.CN) Alpha Cognition Inc. is awaiting an FDA decision on July 27, 2024, for their NDA for ALPHA-1062, targeted at treating mild-to-moderate Alzheimerβs disease. The approval of this drug could offer a new avenue of treatment for Alzheimer's patients.
Xspray Pharma AB (publ) On July 31, 2024, Xspray Pharma AB expects an FDA decision regarding their resubmitted NDA for Dasynoc, intended for the treatment of Chronic Myeloid Leukemia (CML). Approval of Dasynoc could provide an important new therapy for CML patients.
Zevra Therapeutics, Inc. (ZVRA) Zevra Therapeutics, Inc. is set for an FDA panel review on August 2, 2024, for their NDA for Arimoclomol, designed to treat Niemann-Pick disease type C. This rare disease treatment is eagerly anticipated by the medical community and patients alike.
Happy investing,
Maeve Grace
Editor In Chief
Premium Trade Alerts
Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.
Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.
Reply